In order to enhance innovation strength, the introduction of new drugs by pharmaceutical companies has become an upsurge

With the continuous advancement of medical reform, current pharmaceutical companies have begun to passively or actively join the wave of transformation and upgrading
.
It is worth noting that at the same time, more and more local pharmaceutical companies have begun to introduce new drugs to enrich their product pipelines and enhance their innovation competitiveness
.
Recently, Sihuan Pharmaceutical issued an announcement stating that its subsidiary Xuanzhu Biology and SignalChem Lifesciences ("SignalChem") have discussed the development of a highly active and selective AXL targeting inhibitor SLC-391 in Greater China.
Signed a cooperation and licensing agreement with commercial rights
.
According to the agreement, Xuanzhu Bio will make a down payment of USD 13 million to SignalChem
.
In addition, SignalChem is also eligible to receive up to US$208 million in potential development, registration and commercialization milestone payments, as well as tiered sales shares
.
Xuanzhu Bio will obtain the exclusive right to research, develop, manufacture and commercialize SLC-391 in the Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) for various indications in the field of tumor therapy
.
It is understood that SLC-391 is an effective, highly selective, and oral small molecule AXL inhibitor
.
In the future, both parties will use their respective resource advantages to accelerate the approval of SLC-391 in China
.
On September 23, Shenzhen Xinlitai Pharmaceutical Co.
, Ltd.
(hereinafter referred to as "Xinlitai") also signed an agreement with South Korea D&D PHARMATECH, INC.
(hereinafter referred to as "licensor" or "D&D"), and the total amount No more than 27 million U.
S.
dollars, and the method of paying D&D sales share according to a certain percentage of annual net sales, obtains the exclusive license of the intellectual property rights and technical information (hereinafter referred to as "DD01") of the innovative drug DD01 owned by D&D in mainland China
.
Data show that DD01 is a specific dual-target agonist, which selectively activates GLP-1 (glucagon-like peptide-1) receptor and GCGR (glucagon receptor) receptor, stimulating downstream pathways and producing Biological effects such as lowering blood sugar, lowering weight, lowering liver fat, lowering serum cholesterol and improving liver function
.
In addition to the above companies, in September, Genting Xinyao, Haisco, Saisheng Pharmaceutical, Hengrui Pharmaceuticals, etc.
also introduced a batch of new drugs to consolidate their position in certain therapeutic fields and supplement existing pipelines.

.
In this regard, the industry believes that now domestic pharmaceutical companies have reached the time of transformation and upgrading and pulling the gap, so they are accelerating the shift from generic drugs to innovative drugs, from sales-driven to product-driven
.
From the perspective of Hengrui and other large pharmaceutical companies that are actively license-in (authorized introduction), China's innovative drug research and development has entered a new parallel stage of "self-research + cooperative research and development after authorized introduction" from the follow-up fully independent research and development model
.
The industry predicts that in the future, in the context of domestic policies that vigorously promote innovation, the trend of domestic horizontal cooperation (License-in/strategic investment) will become clearer, and even the tide of mergers and acquisitions may come in the past few years
.